Aktive Positionen von Thomas F. Tedder
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
Cellective BioTherapy, Inc.
 Cellective BioTherapy, Inc. Pharmaceuticals: MajorHealth Technology Cellective BioTherapy, Inc. engages in the research and development of novel cellular and monoclonal antibody-based platforms for treating cancers, autoimmunity, and immunodeficiency. Its proprietary pipeline and technology platform focuses on the unique aspects of B cell biology that are involved in regulating a variety of autoimmune diseases and inflammatory immune responses. The company was founded by Thomas F. Tedder in 2015 and is headquartered in Durham, NC. | Direktor/Vorstandsmitglied | 01.01.2015 | - |
| Vorstandsvorsitzender | 01.01.2015 | - | |
| Gründer | 01.01.2015 | - |
Karriereverlauf von Thomas F. Tedder
Ehemalige bekannte Positionen von Thomas F. Tedder
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
Cellective Therapeutics, Inc.
 Cellective Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Cellective Therapeutics, Inc. provides biopharmaceuticals products. It develops monoclonal antibodies for the treatment of oncology and autoimmune diseases. Cellective Therapeutics products include monoclonal antibodies that target the B-cell antigens CD19, CD20 and CD22 are in preclinical stage programs. It was founded by Thomas F. Tedder and Alter E. Geller in May, 2003 and is headquartered in Durham, NC | Technik-/Wissenschafts-/F&E-Leiter | 01.05.2003 | 14.11.2008 |
| Gründer | 01.05.2003 | 14.11.2008 |
Statistik
International
| Vereinigte Staaten | 3 |
Operativ
| Founder | 2 |
| Chief Tech/Sci/R&D Officer | 1 |
| Director/Board Member | 1 |
Sektoral
| Health Technology | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Private Unternehmen | 2 |
|---|---|
Cellective Therapeutics, Inc.
Cellective Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Cellective Therapeutics, Inc. provides biopharmaceuticals products. It develops monoclonal antibodies for the treatment of oncology and autoimmune diseases. Cellective Therapeutics products include monoclonal antibodies that target the B-cell antigens CD19, CD20 and CD22 are in preclinical stage programs. It was founded by Thomas F. Tedder and Alter E. Geller in May, 2003 and is headquartered in Durham, NC | Health Technology |
Cellective BioTherapy, Inc.
Cellective BioTherapy, Inc. Pharmaceuticals: MajorHealth Technology Cellective BioTherapy, Inc. engages in the research and development of novel cellular and monoclonal antibody-based platforms for treating cancers, autoimmunity, and immunodeficiency. Its proprietary pipeline and technology platform focuses on the unique aspects of B cell biology that are involved in regulating a variety of autoimmune diseases and inflammatory immune responses. The company was founded by Thomas F. Tedder in 2015 and is headquartered in Durham, NC. | Health Technology |
- Börse
- Insiders
- Thomas F. Tedder
- Erfahrung
